{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:44:58Z","timestamp":1789825498616,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic inflammation and cachexia are associated with adverse clinical outcomes in diffuse large B-cell lymphoma (DLBCL). The Geriatric Nutritional Risk Index (GNRI) is one of the main parameters used to assess these conditions, but its efficacy in DLBCL is inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 228 DLBCL patients who were treated with R-CHOP immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). The patients were stratified according to GNRI score (&gt;\u200998, 92 to 98, 82 to &lt;\u200992, and\u2009&lt;\u200982) as defined in previous studies. Additionally, the extent of sarcopenia was categorized as sarcopenia-both, sarcopenia-L3\/PM alone, and non-sarcopenia-both according to skeletal muscle index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Survival curves plotted against a combination of GNRI and sarcopenia scores revealed two clear groups as follows: high cachexia risk (HCR) group (GNRI &lt;\u200982, sarcopenia-both, or GNRI 82\u201392 with sarcopenia-L3\/PM alone) and low cachexia risk (LCR) group (others). The HCR group had a lower complete response rate (46.5% vs. 86.6%) and higher frequency of treatment-related mortality (19.7% vs. 3.8%) and early treatment discontinuation (43.7% vs. 8.3%) compared with the LCR group. The median progression-free survival (PFS) (not reached vs. 10.3\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) and overall survival (OS) (not reached vs. 12.9\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) were much shorter in the HCR group than in the LCR group. On multivariable analyses, the HCR group was shown to be an independent negative prognostic factor for PFS and OS after adjusting the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A combined model of GNRI and sarcopenia may provide prognostic information independently of the NCCN-IPI in DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06921-2","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T15:03:43Z","timestamp":1589814223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Se-Il","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon-Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"6921_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790\u20135.","journal-title":"Am J Hematol"},{"key":"6921_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"6921_CR3","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"6921_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors P","year":"1993","unstructured":"International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"6921_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood."},{"key":"6921_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood."},{"key":"6921_CR7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood."},{"key":"6921_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"6921_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3109\/10428194.2014.953142","volume":"56","author":"A Tucci","year":"2015","unstructured":"Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the lymphoma Italian Foundation (FIL). Leuk Lymphoma. 2015;56:921\u20136.","journal-title":"Leuk Lymphoma"},{"key":"6921_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"6921_CR11","volume-title":"Chowdhry VK","author":"SM Chowdhry","year":"2019","unstructured":"Chowdhry SM. Chowdhry VK. Curr Opin Support Palliat Care: Cancer cachexia and treatment toxicity; 2019."},{"key":"6921_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","volume":"83","author":"KC Fearon","year":"2006","unstructured":"Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study G. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83:1345\u201350.","journal-title":"Am J Clin Nutr"},{"key":"6921_CR13","doi-asserted-by":"crossref","unstructured":"Silva GAD, Wiegert EVM, Calixto-Lima L, Oliveira LC. Clinical utility of the modified Glasgow Prognostic Score to classify cachexia in patients with advanced cancer in palliative care. Clin Nutr. 2019.","DOI":"10.1016\/j.clnu.2019.07.002"},{"key":"6921_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/01635581.2014.867065","volume":"66","author":"S Park","year":"2014","unstructured":"Park S, Han B, Cho JW, Woo SY, Kim S, Kim SJ, et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer. 2014;66:225\u201333.","journal-title":"Nutr Cancer"},{"key":"6921_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.15889","volume":"186","author":"M Burkart","year":"2019","unstructured":"Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, et al. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019;186:45\u201353.","journal-title":"Br J Haematol"},{"key":"6921_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/jcsm.12115","volume":"7","author":"SI Go","year":"2016","unstructured":"Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016;7:567\u201376.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6921_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00277-014-2031-2","volume":"93","author":"S Dalia","year":"2014","unstructured":"Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014;93:1305\u201312.","journal-title":"Ann Hematol"},{"key":"6921_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82:777\u201383.","journal-title":"Am J Clin Nutr"},{"key":"6921_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00277-018-3273-1","volume":"97","author":"Y Kanemasa","year":"2018","unstructured":"Kanemasa Y, Shimoyama T, Sasaki Y, Hishima T, Omuro Y. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. Ann Hematol. 2018;97:999\u20131007.","journal-title":"Ann Hematol"},{"key":"6921_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/CBM-170754","volume":"21","author":"Z Li","year":"2018","unstructured":"Li Z, Guo Q, Wei J, Jin J, Wang J. Geriatric nutritional risk index is not an independent predictor in patients with diffuse large B-cell lymphoma. Cancer Biomark. 2018;21:813\u201320.","journal-title":"Cancer Biomark"},{"key":"6921_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHOE Consultation","year":"2004","unstructured":"Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157\u201363.","journal-title":"Lancet."},{"key":"6921_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629\u201335.","journal-title":"Lancet Oncol"},{"key":"6921_CR23","doi-asserted-by":"publisher","first-page":"47007","DOI":"10.18632\/oncotarget.16552","volume":"8","author":"SI Go","year":"2017","unstructured":"Go SI, Park MJ, Song HN, Kim HG, Kang MH, Kang JH, et al. A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget. 2017;8:47007\u201319.","journal-title":"Oncotarget."},{"key":"6921_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2169\/internalmedicine.45.1549","volume":"45","author":"N Tomita","year":"2006","unstructured":"Tomita N, Kodama F, Motomura S, Koharazawa H, Fujita H, Harano H, et al. Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy. Intern Med. 2006;45:247\u201352.","journal-title":"Intern Med"},{"key":"6921_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000324206","volume":"126","author":"F Gaudio","year":"2011","unstructured":"Gaudio F, Giordano A, Perrone T, Pastore D, Curci P, Delia M, et al. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol. 2011;126:44\u201351.","journal-title":"Acta Haematol"},{"key":"6921_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00277-015-2438-4","volume":"94","author":"HS Hwang","year":"2015","unstructured":"Hwang HS, Yoon DH, Suh C, Huh J. Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified. Ann Hematol. 2015;94:1655\u201365.","journal-title":"Ann Hematol"},{"key":"6921_CR27","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.2011.39.2100","volume":"30","author":"KR Carson","year":"2012","unstructured":"Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3217\u201322.","journal-title":"J Clin Oncol"},{"key":"6921_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.6004\/jnccn.2016.0136","volume":"14","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, et al. High body mass index in elderly patients with DLBCL treated with rituximab-containing therapy compensates for negative impact of male sex. J Natl Compr Cancer Netw. 2016;14:1274\u201381.","journal-title":"J Natl Compr Cancer Netw"},{"key":"6921_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/annonc\/mdt594","volume":"25","author":"F Hong","year":"2014","unstructured":"Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014;25:669\u201374.","journal-title":"Ann Oncol"},{"key":"6921_CR30","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/10428194.2013.816421","volume":"55","author":"H Lanic","year":"2014","unstructured":"Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma. 2014;55:817\u201323.","journal-title":"Leuk Lymphoma"},{"key":"6921_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ejh.12285","volume":"93","author":"V Camus","year":"2014","unstructured":"Camus V, Lanic H, Kraut J, Modzelewski R, Clatot F, Picquenot JM, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol. 2014;93:9\u201318.","journal-title":"Eur J Haematol"},{"key":"6921_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jcsm.12161","volume":"8","author":"MP Chu","year":"2017","unstructured":"Chu MP, Lieffers J, Ghosh S, Belch A, Chua NS, Fontaine A, et al. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. J Cachexia Sarcopenia Muscle. 2017;8:298\u2013304.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6921_CR33","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-015-2499-4","volume":"94","author":"N Nakamura","year":"2015","unstructured":"Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol. 2015;94:2043\u201353.","journal-title":"Ann Hematol"},{"key":"6921_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hon.2233","volume":"34","author":"O Bairey","year":"2016","unstructured":"Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34:184\u201392.","journal-title":"Hematol Oncol"},{"key":"6921_CR35","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1158\/1078-0432.CCR-04-0435","volume":"10","author":"CL Monitto","year":"2004","unstructured":"Monitto CL, Dong SM, Jen J, Sidransky D. Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res. 2004;10:5862\u20139.","journal-title":"Clin Cancer Res"},{"key":"6921_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/sj.bjc.6601132","volume":"89","author":"AS Whitehouse","year":"2003","unstructured":"Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer. 2003;89:1116\u201322.","journal-title":"Br J Cancer"},{"key":"6921_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argiles","year":"2014","unstructured":"Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14:754\u201362.","journal-title":"Nat Rev Cancer"},{"key":"6921_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.26811","volume":"234","author":"SI Daas","year":"2018","unstructured":"Daas SI, Rizeq BR, Nasrallah GK. Adipose tissue dysfunction in cancer cachexia. J Cell Physiol. 2018;234:13\u201322.","journal-title":"J Cell Physiol"},{"key":"6921_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2362.2008.01970.x","volume":"38","author":"P Costelli","year":"2008","unstructured":"Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Investig. 2008;38:531\u20138.","journal-title":"Eur J Clin Investig"},{"key":"6921_CR40","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","volume":"391","author":"ME Benny Klimek","year":"2010","unstructured":"Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010;391:1548\u201354.","journal-title":"Biochem Biophys Res Commun"},{"key":"6921_CR41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2014.04.012","volume":"61","author":"V Arroyo","year":"2014","unstructured":"Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61:396\u2013407.","journal-title":"J Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06921-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06921-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06921-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T19:15:25Z","timestamp":1621278925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06921-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6921"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06921-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16671\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16671\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Gyeongsang National University Hospital and conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"439"}}